HHS Awards $2.25 Million to 19 Phase 1 Winners of Caregiver AI Challenge for Tools to Strengthen Care
-
By
-
Assistant Secretary for Public Affairs (ASPA)
-
November 18, 2026
By
Assistant Secretary for Public Affairs (ASPA)
November 18, 2026
by Assistant Secretary for Public Affairs (ASPA)
November 18, 2026
Median progression-free survival was 10 vs 5.5 months with giredestrant vs comparator therapy.
by Mouj Hijazi
November 17, 2026
Higher medical expenses increased financial anxiety and reduced willingness to schedule recommended procedures in 3 studies, with stronger effects among financially stressed participants.
November 11, 2026
Sustained remission reached 40.5% with secukinumab vs 20.5% with placebo at 52 weeks, alongside lower steroid exposure.
by Mouj Hijazi
November 17, 2026